Hamburg, Germany, 03 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024. Matthias was appointed Chief Business Officer of Evotec on 01 May 2022.

Prof. Dr Iris Löw-Friedrich, Chairwoman of the Supervisory Board of Evotec, said: “Over the past two-and-a-half years, Matthias has been instrumental in helping Evotec navigate challenging times. His many contributions – in particular establishing Evotec’s biologics segment Just – Evotec Biologics as well as the recovery from the cyber-attack – will have a lasting impact. On behalf of Evotec’s Supervisory Board, I would like to express our sincere gratitude to Matthias for his outstanding work over these past years. We wish Matthias every success in his future endeavours.”

Dr Matthias Evers, Chief Business Officer of Evotec SE, commented: “Thank you to my amazing colleagues across all of Evotec – the passion for medicines that matter is inspiring and the people at Evotec make all the difference. While I have chosen to pursue a new path, I wish Evotec with all colleagues long-term success which I am confident the priority reset will bring.”

Dr Christian Wojczewski, Chief Executive Officer of Evotec, added: “On behalf of the Management Board, I would like to thank Matthias for his commitment and dedication to Evotec for the past two-and-a-half years. He has shown great leadership in challenging times and his contributions will have lasting impact. On a personal note, I would like to thank Matthias for the great onboarding and his ongoing support as his responsibilities transition to other Management Board members.”

As of 01 October, the responsibilities of the CBO function will be distributed across the other Management Board functions.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Media

Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com

Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com